Introduction
A broad variety of antiviral drugs are clinically approved (for an overview, see Ref. [1] ). The majority of these drugs are nucleoside analogues for which the virus-encoded DNA and RNA polymerases are the prime targets for the inhibition of virus replication. Indeed, a variety of nucleoside analogues efficiently inhibit the herpes DNA polymerases encoded by herpes simplex virus type 1 and type 2 [2] , varicella zoster virus (VZV) [2, 3] and human cytomegalovirus (HCMV) [2, 4] , the reverse transcriptase of retroviruses such as HIV-1 and HIV-2 [5] , the DNA polymerase of hepatitis B virus [6] , as well as the RNA polymerases specified by several RNA viruses such as respiratory syncytial virus [7] , influenza viruses [8] , and also flaviviruses as exemplified by hepatitis C virus [9, 10] . Such inhibitors need to be activated (phosphorylated) by virusencoded kinases or by cellular nucleoside/nucleotide kinases to their 5 0 -triphosphate derivatives, or in case of the acyclic nucleoside phosphonates to their diphosphate derivatives before these nucleoside/nucleotide analogues can be recognized by the viral DNA or RNA polymerases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . The nucleoside analogues are often incorporated in the growing viral DNA or RNA chain, and function as chain terminators [2, 5] . Instead, several nonnucleoside derivatives have also been discovered to act against viral polymerases, either at a non-substrate active site of the enzyme [such as the non-nucleoside RT inhibitor (NNRTI) interaction with HIV-1 RT] [11] [12] [13] or at the substrate-active site of the RT enzyme [such as the nucleotide-competing RT inhibitor (NcRTI) (i.e. INDOPY)] [14] [15] [16] . Such agents differ from a classic nucleoside structure and do not need prior metabolic conversion to exhibit inhibitory activity against their specific polymerase target(s).
Members of the nucleoside analogue class of compounds represent the highest number of clinically approved antiviral drugs [1] . However, due to their obligatory dependence on cellular metabolism and often inefficient intracellular conversion to their antivirally-active phosphorylated metabolites, efforts have been devoted to deliver directly and more efficiently the nucleoside/ nucleotide drugs intracellularly as their activated (mono)phosphorylated derivatives [17] [18] [19] [20] . Although this approach proved successful in several cases, the compounds usually still need to be converted to their eventual triphosphate equivalent before being inhibitory against the viral polymerase.
Recently, we have reported an entirely different approach to design nucleotide analogues ( Fig. 1 ) that are directly inhibitory to viral DNA polymerases without the need of additional metabolic conversions [21, 22] . The prototype of these novel nucleotide analogues consists of a nucleobase, connected to an a-carboxy phosphonate moiety through a cyclic cyclopentyl linker entity. Crystallographic, kinetic and biochemical studies have shown that such compounds could directly bind to the substrate-active site of HIV-1 RT without any prior metabolic conversion enabling base pairing and active site Mg 2+ ion chelation similar to the natural dNTPs [21, 23] . It was shown that one oxygen of the carboxylate and two oxygens of the phosphonate part of the a-CNP backbone are involved in Mg 2+ ion coordination. These three oxygens mimic the three chelating a-,b-and c-phosphate oxygen atoms of a dNTP [21, 23] .
Although the thymine-, uracil-, cytosine-and adenine-a-CNPs are potent inhibitors of HIV RT, they are less inhibitory to herpes DNA polymerases [21] . However, the guanine a-CNP derivative had not been synthesized and evaluated in previous studies. Given the importance of guanine nucleoside analogues as antiherpes (i.e. acyclovir, ganciclovir) or anti-HIV (i.e. abacavir) agents, we now synthesized the guanine a-CNP (G-a-CNP) and investigated its inhibitory activity against HIV-1 RT and herpes DNA polymerases. The G-a-CNP derivative displayed comparable inhibitory activity against HIV-1 RT and the herpes DNA polymerases as the prototype thymine-a-CNP, but showed differences in its inhibitory activity against mutant HIV-1 reverse transcriptases. Its mechanism of action appears to be significantly different for HIV-1 versus the herpes DNA polymerases. This novel compound is of interest as a potential dually-active compound with significant concomitant anti-HIV and anti-herpes virus DNA polymerase activity.
Materials and methods

Compound synthesis and characterization data
Racemic G-a-CNP was prepared in nine steps starting from 2-cyclopentenone. The materials were purchased from Acros Organic, Fisher Scientific Ireland Ltd. (Dublin, Ireland). The enantiomers (L)-(+)-G-a-CNP and (D)-(À)-G-a-CNP were prepared in seven steps starting from (1R,4S)-(À)-cis-4-acetoxy-2-cyclopenten-1-ol and (1S,4R)-(+)-cis-4-acetoxy-2-cyclopenten-1-ol, respectively. Full details of the synthesis will be described elsewhere. 
Reverse transcriptase, nucleic acids, and small molecules
HIV-1 reverse transcriptase was expressed and purified as described previously [33] . Oligodeoxynucleotides were synthesized and purchased from Integrated DNA Technologies, Coralville, USA. The following sequence was used as template: PPT57, CGTT GGGAGTGAATTAGCCCTTCCAGTCCCCCCTTTTCTTTTAAAAAGTGGCT AAGA. Primer sequences used were: PPT-17, GCCACTTTTTAAAA GAAAAGGGGGG; PPT+16, AAAGGGGGGACTGGAAGGGCTAATT. Deoxynucleotides were purchased from Integrated DNA Technologies.
DNA synthesis
A 3-fold excess of PPT-57 DNA template was heat-annealed to 50 nM 5 0 -fluorolabeled PPT-17 primer, then incubated with 250 nM of RT in a buffer containing 50 mM Tris-HCl (Sigma, St. Louis, MO), pH 7.8, 50 mM NaCl (Sigma), 0.3 mM EDTA (Sigma), and 0.5 mM of each of dATP, dTTP, dGTP, and dCTP (GE Healthcare, Pittsburgh, PA). The samples were preincubated at 37°C for 5 min before starting the reactions. For inhibitor dose-response experiments, each of the four inhibitors was titrated up to 100 mM, and the reaction was initiated with 6 mM MgCl 2 and allowed to proceed for 3 min. To assess pausing sites, separate reactions with 0.1 mM of either ddATP, ddTTP, ddGTP and ddCTP were run. As a negative control, a sample without dNTP was also included. The reaction was stopped with 100% formamide loading dye containing traces of bromophenol blue. Samples were resolved on a 12% denaturing polyacrylamide gel followed by phosphorimaging (Amersham Biosciences, Piscataway, NJ). For the dose-response experiments, pausing sites caused by inhibition were quantified and summed; the % inhibition was calculated as the total amount of inhibited product divided by the amount of full-length product plus inhibition products, multiplied by 100. The product fractions were normalized and plotted against inhibitor concentration using GraphPad Prism software; the normalized data were fitted to a log [inhibitor] versus response curve with variable slope to extract IC 50 values for the inhibition of the RT enzymes by the a-CNP.
Site-specific footprinting
Chemical footprinting with Fe 2+ of the template strand was conducted using 50 nM 5 0 -fluorolabeled DNA template (PPT-57) annealed to 150 nM of the primer (PPT + 16). The hybrid was incubated with 750 nM HIV-1 RT in a buffer containing 120 mM sodium cacodylate (pH 7), 20 mM NaCl, and 6 mM MgCl 2 in a final volume of 50 lL. Increasing concentrations of G-, T-and A-a-CNP were added to the samples. Samples without inhibitor, enzyme and Fe 2+ treatment were also included. Pre-incubation of complexes at 37°C for 10 min was performed prior to the treatment with Fe
2+
. Treatment with Fe 2+ was performed as previously described [34] .
Reverse transcriptase assay with homopolymeric template/ primers
The HIV-I RT assays were also carried out in the presence of artificial homopolymeric template/primers. Poly(A), dT [12] [13] [14] [15] [16] [17] [18] , dC [12] [13] [14] [15] [16] [17] [18] , poly(I), dA [12] [13] [14] [15] [16] [17] [18] and poly(C), dG [12] [13] [14] [15] [16] [17] [18] were from Pharmacia (Uppsala, Sweden). To prepare the template/primers for the RT experiments, 0.15 mM poly(C) and poly(A) were mixed with an equal volume of 0.0375 mM oligo(dG) and oligo(dT), respectively. The reaction mixture (50 ml) contained 50 mM Tris.HCl (Sigma, Overijse, Belgium) pH 7.8, 5 mM dithiothreitol (Roche, Vilvoorde, Belgium), 300 mM glutathione (Sigma), 500 mM EDTA (Sigma), 150 mM KCl (Sigma), 5 mM MgCl 2 (Sigma), 1.25 mg of bovine serum albumin (Sigma), an appropriate concentration of the tritium-labeled substrate [CH 3 -3 H]dTTP or [ 3 H]dGTP (2 mCi/assay) (Moravek Biochemicals, Brea, CA), a fixed concentration of the template/primer poly(A). oligo(dT) (0.015 mM) or poly(C).oligo(dG) (0.015 mM), 0.06% Triton X-100 (Sigma), 10 ml of a-CNP inhibitor solution (containing various concentrations of the compounds), and 1 ml of the HIV-1 RT preparation. The reaction mixtures were incubated at 37°C for 30 min, at which time 100 ml of calf thymus DNA (GE Healthcare, Diegem, Belgium) (150 mg/ml), 2 ml of Na 4 P 2 0 7 (Sigma) (0.1 M in 1 M HCl), and 2 ml of trichloroacetic acid (Merck, Darmstadt, Germany) (10% v/v) were added. The solutions were kept on ice for 30 min, after which the acid-insoluble material was washed and analyzed for radioactivity. For 
Enzyme assay with HCMV DNA polymerase
The pGEM3Z-CMV UL54 plasmid for expression of the catalytic subunit (UL54 protein) of HCMV DNA polymerase was a generous gift from T. Cihlar (Gilead Sciences, Foster City, CA) [35] . Protein expression was performed with the TnT Ò SP6 Quick Coupled Transcription/Translation System (Promega) [36] . The plasmid was added (at 10 ng per ml volume) to the TnT Ò mix containing 0.5 mM MgCl 2 and 10 mM potassium acetate (Janssen Chimica, Beerse, Belgium), and the mixture was incubated for 3 h at 30°C. To perform the HCMV DNA polymerase assay, 4 ml of the TnT Ò reaction product was added to a 46 ml mixture to obtain 25 mM Tris.HCl pH 8.0, 100 mM (NH 4 ) 2 SO 4 (Sigma), 0.5 mM dithiothreitol, 10 mM MgCl 2 , 0.2 mg/ml bovine serum albumin, 5% glycerol (Acros, Geel, Belgium), 150 ng per ml activated calf thymus DNA (from Amersham Biosciences, Piscataway, N.J.), 100 mM of each of the three unlabeled dNTPs (GE Healthcare), and 0.5 mM of the rate-limiting tritium-labeled dNTP, and serial dilutions of the a-CNP. After 60 min incubation at 37°C, nucleic acids were precipitated by addition of 1 ml of ice-cold 5% TCA and 20 mM Na 4 P 2 O 7 , then spotted onto glass microfiber filters (type G/C; GE Health Care UK Limited, Buckinghamshire, UK) and further washed with 5% TCA and ethanol (BDH Prolabs, Dawsonville, GA) to remove free radiolabeled dNTP. Radioactivity was determined in a Packard (Perkin Elmer, Zaventem, Belgium) Tri-Carb 2300 TR liquid scintillation counter. All radiolabeled materials were obtained from Moravek (Brea, CA).
2.7.
Enzyme assay with herpes simplex virus type 1 (HSV-1) DNA polymerase and cellular DNA polymerases a and b
HSV-1 DNA polymerase catalytic subunit (UL30) was expressed in S. frugiperda cells and purified as previously described [37] . The experiments described here used UL30 fraction V. The reaction mixture (40 ml) for the HSV-1 DNA polymerase and cellular DNA polymerase a and b assays contained 4 ml of Premix (200 mM Tris.HCl pH 7.5; 2 mM DTT; 30 mM MgCl 2 ), 4 ml of BSA (5 mg/ml), 1.6 ml of activated calf thymus DNA (1.0 mg/ml), 0.8 ml of dCTP (5 mM), 0.8 ml of dATP (5 mM), 0.8 ml of dTTP (5 mM), 2 ml of radiolabeled , and the reaction mixture was incubated for 60 min at 37°C. Then, 1 ml of ice-cold 5% TCA in 0.02 M Na 4 P 2 O 7 .10 H 2 O was added to terminate the polymerization reaction. The consecutive steps (i.e. capture of the acid-insoluble precipitate onto filters, filter washing and scintillation counting) were done as described above.
Kinetic analysis
The nature of the kinetic interaction of the inhibitors was analyzed by the mixed model using a non-linear regression method available in GraphPad. The mixed model uses a general equation including competitive, uncompetitive and noncompetitive inhibition as special cases. The following equations were used: V max
, in which X is substrate concentration, Y is enzyme activity, V max is maximum enzyme velocity, K m = Michaelis-Menten constant, I is inhibitor concentration, K i = inhibition constant, and a is a constant that determines the kinetic mechanism. When a = 1, kinetics are noncompetitive. When a is very large, the kinetic model approaches a competitive interaction; when a is very small (but greater than zero), the kinetic model approaches an uncompetitive interaction.
Results
G-a-CNP inhibits HIV and herpes DNA polymerases, but not cellular DNA polymerases
The inhibitory activity of G-a-CNP was first evaluated against HIV, herpes (i.e. HSV-1, HCMV) and cellular DNA polymerases a and b as a racemic mixture of (D)-(À) and (L)-(+). The inhibition by NRTI ddGTP, the pyrophosphate analogue PFA, the NNRTI nevirapine, the NcRTI INDOPY-1, and the prototype (L)-(À)-thymine-a-CNP was determined in this study for comparison ( Table 1) . The (±) G-a-CNP analogue markedly inhibited HIV-1 RT when poly rC.dG and [
3 H]dGTP were used as the homopolymeric template/primer and dNTP substrate, respectively, but not in the presence of poly rA.dT and [
3 H]dTTP. This homopolymeric template/primer-dNTP selectivity was in agreement with the earlier findings that the prototype T-a-CNP was only inhibitory to HIV-1 RT in the presence of its corresponding homopolymeric template/primer poly rA.dTdTTP, but not when any other template/primer-dNTP pair, including poly rC.dG and dGTP, were used (21) . These data point to a nucleobase (i.e. guanine)-specific inhibition of dNTP (i.e. dGTP) incorporation into the corresponding homopolymeric template/ primer by (±)-G-a-CNP. The (±)G-a-CNP was an equally potent inhibitor of HIV-1 RT as the (±)T-a-CNP derivative [IC 50 : 0.62 mM and 0.41 mM (21), respectively] ( Table 1) .
The Table 1) . The (L)-(+)-G-a-CNP derivative was equally inhibitory to HIV-1 RT as 2 0 ,3 0 -dideoxyguanosine-5 0 -triphosphate (ddGTP), however, at higher efficacy than PFA, nevirapine, and INDOPY-1 in the presence of the poly rC.dG-dGTP template/primer-dNTP system.
In contrast with HIV-1 RT, inhibition of herpes (i.e. HSV-1, HCMV) DNA polymerases by (±)G-a-CNP was independent of the nature of the competing dNTP used (Table 1) . Thus, (±)-G-a-CNP inhibited HSV-1 and HCMV DNA polymerases at the same order of magnitude when either dGTP or dTTP were used as the competing radiolabeled substrate (IC 50 0 s ranging between 8 and 32 mM for (±)G-a-CNP and between 4. The homopolymeric template/primer-dGTP-dependent specificity of G-a-CNP against HIV-1 RT strongly suggests competitive inhibition with respect to the incoming corresponding dNTP.
Therefore, enzyme inhibition kinetics have been investigated for (±)-G-a-CNP. The data were visualized through Lineweaver-Burk reciprocal substrate versus velocity plots and analyzed with the mixed model using a non-linear regression method available in Graph Pad (Table 2 ). (±)-G-a-CNP was indeed found to competitively inhibit dGTP incorporation into the template/primer poly rC.dG (Fig. 2, panel A) (alpha-value in the mixed model being 1.799) and was shown to suppress the DNA polymerization by HIV-1 RT at a strong trend of non-competitive inhibition with regard to the template/primer (Fig. 2, panel B) (alpha-value in the mixed model being 0.147).
The nature of the kinetic interaction of (±)-G-a-CNP for the herpes DNA polymerases of HSV-1 and HCMV was clearly different. Instead of competitive inhibition with respect to the dGTP for HIV-1 RT, a most likely mode of noncompetitive kinetics was observed for the HSV-1 and HCMV DNA polymerases using calf thymus DNA and [ 3 H]dGTP as the template/primer and radiolabeled dNTP substrate (Fig. 2, panels C & D) (alpha-value in the mixed model being 0.386 and 0.905, respectively) ( Table 2 ). Our kinetic study findings also imply that (±)G-a-CNP interacts with the substrate-active site of HIV-1 RT, but seems to bind to a loca- (Fig. 3) . In Table 3 , the kinetic parameters obtained from the non-linear regression analysis by GraphPad for the fitting of the different inhibition models are shown.
3.3. The G-a-CNP derivative retards dNTP incorporation and traps the RT in the post-translational state, but does not incorporate into the HIV-1 RT-catalyzed growing DNA chain HIV-1 RT-catalyzed DNA synthesis was studied in a gel-based assay to gain more insights into the mechanism of drug action. A heteropolymeric DNA was used with a well-defined nucleotide sequence. All four types of a-CNPs containing either adenine, thymine, cytosine, or guanine nucleobase were included for comparison. The experiments showed specific nucleobase-dependent HIV-1 RT inhibition patterns. A dose-dependent inhibition of DNA synthesis was observed at a single nucleotide site before the predicted location on the template at which the a-CNP would interact (compete) with its complementary natural template nucleobase. Thus, the HIV-1 RT-catalyzed nucleotide extension of the template/primer complex by dGTP was dose-dependently retarded in the presence of (±)-G-a-CNP but not A-, T-or C-a-CNP (most right (fifth) lane series, Fig. 4) . Likewise, the a-CNPs containing the other nucleobases behaved also selectively depending on the nature of the competing corresponding natural nucleotide (second, third, and fourth lane series, Fig. 4 ). The IC 50 s of HIV-1 RT inhibition in the gel-based assay were calculated to be 3.1 ± 2.0, 3.6 ± 1. (Fig. 5) .
Inhibition of HIV-1 RT by G-a-CNP is influenced by amino acid mutations in the vicinity of the active site
The (±)-G-a-CNP analogue has been analyzed for its sensitivity against a wide variety of mutant HIV-1 RTs, and the fold-resistance values versus wild-type RT were compared with those obtained for the corresponding T-, C-, and A-a-CNP analogues as well as for the NcRTI INDOPY-1 ( Table 4) . Several of the mutations in HIV-1 RT have been chosen among those that were reported to play a role in susceptibility to INDOPY-1 [14, 25] , interact with the cyclopentyl ring of T-a-CNP in the crystal structure (i.e. Y115, Q151, and M184) [21] , or affect polymerase translocation and fidelity (i.e. F61A, Y115F) [26, 27] . The most striking degrees of sensitivity loss for (±)-G-a-CNP were displayed by the F61A mutant RT enzymes (79-fold), followed by RTs containing the M184I/V (8.7-to 19-fold) and the V75I (8.7-fold) mutation (Table 2) . Slight sensitization was observed for the K70E/Q (0.7-fold) mutations, but not for the K70R mutation (2.6-fold). Also, the NNRTI-characteristic L100I and Y181C resistance mutations caused a 5.2-fold resistance, but not the K103N (1.1-fold), V106A (1.6-fold) and E138K (0.9-fold) mutations. The Y115F mutation conferred 2.3-fold resistance against (±)-G-a-CNP. Interestingly, when M184V was combined with Y115F, the resistance level markedly (synergistically) increased (39-fold). The multidrug resistance-associated mutation Q151M afforded a 3.1-fold lower sensitivity to (±)-G-a-CNP than the wild-type enzyme.
When the effects of the HIV-1 RT mutations on the (±)-G-a-CNP's inhibitory potential were compared with their effects on the sensitivities of the mutant enzymes for the corresponding A-, C-, and T-a-CNPs, a number of interesting observations could be made: (i) Depending on the nature of the nucleobase, the sensitivity level against the mutant enzymes sometimes differed quite substantially. For example, the F61A mutation conferred its most pronounced effects on the G and T analogues (79-and 31-fold, respectively), whereas the A and C analogues were much less affected by this mutation (3.9-and 5.2-fold, respectively). Also, the M184I/V mutations showed 8.7-to 19-fold, 11-to 12-fold, or 16-to 36-fold decreased sensitivity for the G-, C-and T-a-CNP analogues, respectively, but only 1.7-to 2.8-fold decreased sensitivity for the A-a-CNP analogue. (ii) Whereas a slight sensitization was observed for the G-analogue against the mutant K70E/Q enzymes (0.7-fold), such sensitization was more pronounced for C-a-CNP (0.2-to 0.3-fold), but was not significantly present for the Tanalogue (0.8-to 1.1-fold), whereas the A-analogue was rather endowed with a 3-to 3.7-fold decreased inhibitory potential. Sensitization was also observed for C-a-CNP against the V106A (0.2-fold) and the Q151M (0.4-fold) mutations and to a lesser extent for the A-a-CNP (in both cases 0.8-fold), but absent for the Gand T-analogues (1.1-to 3.1-fold). (iii) When the inhibition spectrum of C-a-CNP was compared with INDOPY-1, a striking similarity could be observed, although the absolute levels of decreased sensitivity/hypersensitivity degree was usually (but not always) less pronounced for INDOPY-1. For example, the sensitization of C-a-CNP inhibition against K70E/Q, V106A and Q151M (0.2-to 0.4-fold) was also observed for INDOPY-1 (0.2-to 0.7-fold), as was also decreased sensitivity to the C-a-CNP (11-to 12-fold) and INDOPY-1 (!6.7-fold) by the mutant M184I/V enzymes. (iv) Whereas the F61A mutation gave consistently the most striking fold-decrease in sensitivity against all a-CNPs, it hardly affected the inhibitory potential of INDOPY-1 (1.9-to 2.2-fold). (v) Although the G-, A-, C-and T-a-CNPs show nucleobase-specific inhibitory activity against HIV-1 RT irrespective of the nature of the tem- plate/primer and competing dNTP (but corresponding to the nucleobase present in the a-CNPs), INDOPY-1 showed only inhibitory activity when competing with pyrimidine nucleotides (dCTP and dTTP), but not purine nucleotides (dGTP or dATP), as also previously reported (14) .
Taken all data together, it seems that the decreased inhibition of (±)-G-a-CNP is highest for the mutant RT enzymes that contain changes in amino acids lining the substrate-binding pocket (i.e. V75I, M184I/V) or interact with the template overhang (i.e. F61A). On the other hand, the absolute levels of decreased sensitivity (or hypersensitization) can markedly differ depending on the nature of the nucleobase, pointing to subtle differences in the positioning of the a-CNPs in the substrate-active site of HIV-1 RT.
Modeling of (L)-(+)-G-a-CNP in the substrate-binding site of HIV-1 RT
The G-a-CNP derivative has been modeled in the substratebinding site pocket of HIV-1 RT. Analogous to T-a-CNP, binding of a G-a-CNP should satisfy the metal chelation, and interactions with a dCMP as the first base overhang. We used the crystal structure of the RT/DNA/T-a-CNP ternary complex (21, 23) to model an RT/DNA/G-a-CNP complex (Fig. 6) , in which the metal chelation geometry, and the conformation and interactions of the cyclopentane ring of G-a-CNP were assumed to be very similar to those of T-a-CNP. Analogous to the conformation of a-CNP of the RT-bound T-a-CNP, (L)-(+)-G-a-CNP, but not (D)-(À)-G-a-CNP, binds favorably at the dNTP-binding site. Residue F61 is located at the base of the b3-b4 fingers' loop, and its aromatic side chain is positioned between the first and second template overhangs. Additionally, the side chains of F61, I63, and L74 form a hydrophobic cluster, and the cluster appears to have impact on dNTP binding, incorporation, and excision via repositioning of the template overhang. The L74V mutant RT is less fit for nucleotide incorporation and for excision [28, 29] . Molecular modeling suggested that L74V might be affecting the positioning of the first template overhang [30] . The crystal structures of HIV-1 RT/DNA/dATP (or dTTP) were compared to assess differences in the mode of binding of a purine vs. pyrimidine nucleobase, but no significant difference was observed between the bound states of dATP vs. dTTP. However, the dynamic steps leading to (i) the binding and (ii) incorporation of a dNTP, and (iii) translocation after the incorporation might be somewhat dependent on specific nucleobase. HIV-1 RTs containing AZT-resistance mutations (or TAM) that efficiently excise AZT (3 0 -azido-ddT) do not effectively excise AZG (3 0 -azido-ddG) [31] , which may suggest subtle differences in the preferred positioning of the individual dNTPs and their analogues before and after incorporation. We observed significant differences in resistance to A-, T-, G-, and C-a-CNP derivatives by mutant F61A RT (Table 4) . F61A mutation might affect the positioning of the template overhang, and the effect may be different on different types of nucleobases to exhibit and explain the diverse impact on a-CNP analogues.
Discussion
We recently reported on a-carboxynucleoside phosphonates as a novel class of nucleoside phosphonate derivatives that do not need metabolic activation to efficiently interact with the virusencoded DNA polymerases (21, 22) . Interestingly, crystallographic, biochemical and kinetic studies revealed that these compounds bind like N(t)RTIs in the substrate-binding pocket of HIV-1 RT, compete with dNTPs that contain the same nucleobase as the a-CNP but, in contrast with NRTIs and NtRTIs, are not covalently attached to the primer (21) . Whereas these compounds were relatively potent inhibitors of HIV reverse transcriptase (IC 50 0 s in the nanomolar range), they proved clearly less inhibitory to herpes (i.e. HSV-1, VZV, HCMV) DNA polymerases (IC 50 0 s in the micromolar range) (21) .
We have now synthesized the corresponding guanine derivative, and demonstrated that it had comparable inhibitory potencies as the prototype T-a-CNP analogue against HIV-1 RT and the HSV-1/HCMV DNA polymerases. Interestingly, whereas G-a-CNP was a competitive inhibitor of HIV-1 RT with respect to the natural dGTP substrate, G-a-CNP showed non-or uncompetitive inhibition with respect to the natural substrate against the HSV-1 and HCMV DNA polymerases. As a result, the lack of competitive kinetics against the herpes DNA polymerases are suggestive for an independent mutually non-exclusive binding of G-a-CNP and the corresponding natural dNTP to the herpes DNA polymerases, and, therefore, G-a-CNP is not expected to interact with the substrate-binding site of the herpes DNA polymerases. Such a distinct kinetic nature of enzyme interaction between HIV-1 versus herpes DNA polymerases is unusual and unprecedented for a single drug molecule, reflecting molecular and functional diversity between different enzymes that have similar enzymatic functionalities. Since the crystallographic complex of HIV-1 RT with a-CNPs such as T-a-CNP revealed binding of the compound in the substrate-binding pocket of HIV-1 RT and G-a-CNP could also be modeled into the HIV-1 RT enzyme's active site, it would be very interesting to obtain crystallographic complexes of the a-CNPs (i.e. G-a-CNP) with the herpes DNA polymerase(s) to reveal and define the binding pocket of the a-CNPs in these herpesvirus-encoded enzymes.
According to the nature of the observed kinetics, binding to the polymerase dNTP substrate active-site domain of the herpes DNA polymerase is rather unlikely. It cannot be excluded that the (D)-and (L)-G-a-CNP derivatives are still able to interact with the pyrophosphate binding site of the herpetic DNA polymerases in such a manner that independent binding of dNTP to the substrate active site is still allowed. However, alternatively, the 3 0 ,5 0 -exonuclease domain of the herpes enzymes may also be a potential candidate site for binding of the a-CNPs. In fact, it has been demonstrated that the antiherpes drug acyclovir (as its triphosphate derivative) can bind to the active site of HSV-1 DNA polymerase (competitive to dGTP binding) keeping the 3 0 ,5 0 -exonuclease activity unaffected [32] . This means that both polymerase and 3 (14), also act as compromising RT mutations for G-a-CNP inhibitory activity. However, other mutations such as F61A markedly affect G-a-CNP inhibition, but not INDOPY-1 inhibition. It should, however, be noted that the RT sensitivity spectrum of the a-CNPs highly depended on the nature of the nucleobase, a property that is also the case for NRTIs when the resistance mutation spectrum of NRTIs with different nucleobases (i.e. AZT, ddI, ddC, and carbovir) were compared.
Whereas INDOPYs and a-CNPs share many kinetic and biochemical similarities with regard to HIV-1 RT inhibition, inhibition of HIV-1 RT by INDOPYs is independent from Mg 2+ interactions and are devoid of any anti-herpes DNA polymerase activity. Thus, although being NcRTIs, the a-CNPs, in casu G-a-CNP inhibit also herpes DNA polymerases, qualifying them as novel inhibitors of multiple viral DNA polymerases.
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